Loading
Pi3k/akt/mtor Signaling in Cancer / Cancer, Stress, Anesthesia, and Immune Response · Journal article
Macromolecular Symposia · August 16, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review summarizing mTOR signaling biology, its dysregulation in cancer, and the conceptual rationale for mTOR inhibitor development. It describes mechanistic promise and emerging nanoparticle delivery approaches but does not present clinical trial results, efficacy data, or comparative effectiveness evidence.
Narrative review. Malignancy (cancer) broadly; no specific cancer type, stage, or patient cohort studied.
mTOR is deregulated in over 30% of malignancies, making it a potential therapeutic target mTOR inhibitors are being studied as potential cancer therapies, with some medications demonstrated to be highly effective when combined with mTOR inhibitors Nanoparticle-based mTOR modulators are anticipated to improve bioavailability and reduce adverse effects
No data on adverse effects, survival, response rates, or other hard endpoints Nanoparticle-based mTOR modulators are anticipated to improve bioavailability and reduce adverse effects
This review contextualizes mTOR as a target of interest and describes the biological rationale for pursuing mTOR inhibitors, but provides no evidence base for clinical decision-making. Clinicians should consult clinical trial evidence and regulatory approvals for specific mTOR inhibitors and cancer indications.
This is a narrative review of mechanistic pathways and drug development concepts, not a clinical trial or meta-analysis, and raises questions about mTOR inhibitors rather than testing them in humans with measured outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This review contextualizes mTOR as a target of interest and describes the biological rationale for pursuing mTOR inhibitors, but provides no evidence base for clinical decision-making. Clinicians should consult clinical trial evidence and regulatory approvals for specific mTOR inhibitors and cancer indications.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT The mammalian target of rapamycin (mTOR) serine/threonine protein kinase known to be an important regulator of cellular growth, protein translation, cell proliferation, cell survival, metabolism, and autophagy. It is known to be activated by intracellular as well as extracellular signals, such as nutrient availability, growth factors, and energy levels of cells. The frequent deregulation of mTOR signaling in over 30% of malignancies makes it a promising key target for cancer therapy. Many mTOR inhibitors have been developed and undergone clinical trials, and many medications have been demonstrated to be highly effective when combined with mTOR inhibitors. Direct inhibition of the mTOR pathway is a new field in cancer therapy with the potential to control growth factors as well as estrogen‐dependent and estrogen‐independent pathways that contribute to tumor pathology and progression. Thus, mTOR inhibitors are being studied as potential cancer therapies. Recently, nanoparticle‐based mTOR modulators have been anticipated to target numerous malignancies while also delivering and releasing medications in a controlled manner, resulting in improved bioavailability and fewer adverse effects. This review focusses on the mammalian target of rapamycin signaling pathway, including its current status and obstacles in cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.